FGP
WST icon

Freestone Grove Partners’s West Pharmaceutical WST Stock Holding History

Freestone Grove Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Buy
5,570
+5,478
+5,954% +$1.67M 0.01% 424
2026
Q1 		$23.1K Sell
92
-2,434
-96% -$606K ﹤0.01% 863
2025
Q4 		$695K Sell
2,526
-163,816
-98% -$44.8M 0.01% 517
2025
Q3 		$43.6M Buy
166,342
+165,239
+14,981% +$40.2M 0.33% 108
2025
Q2 		$241K Sell
1,103
-141,873
-99% -$30.3M ﹤0.01% 612
2025
Q1 		$32M Buy
+142,976
New +$39.4M 0.33% 110

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Freestone Grove Partners's WST Position: Q2 2026 in Review

Freestone Grove Partners increased its West Pharmaceutical (WST) stake by 5,954% in Q2 2026, buying an estimated $1.67M and bringing the position to 5,570 shares worth $2M. The position accounts for 0.01% of the portfolio, ranked #424.

Freestone Grove Partners first reported a position in WST in Q1 2025 and has held it in 6 quarters since. The position peaked at $43.6M in Q3 2025. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Freestone Grove Partners held 5,570 shares of West Pharmaceutical worth $2M as of Q2 2026.
  • Freestone Grove Partners bought 5,478 West Pharmaceutical shares in Q2 2026, an estimated $1.67M.
  • West Pharmaceutical made up 0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #424 holding.
  • Freestone Grove Partners first reported a position in West Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • Freestone Grove Partners's West Pharmaceutical position peaked at $43.6M in Q3 2025.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.